search
Back to results

Circumferential Vertebral Reconstruction of Osteoporotic Compression Fractures Using a Novel Bipedicular Peek Implant (RECONSTRUCT)

Primary Purpose

Vertebral Compression Fractures, Osteoporotic Vertebral Compression Fractures

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Vertebral Implant PEEK Procedure
Vertebral Implant PEEK (VIP) implant
Sponsored by
Icahn School of Medicine at Mount Sinai
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Vertebral Compression Fractures

Eligibility Criteria

50 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age>50
  • Osteoporotic compression fractures of the thoracolumbar spine (T9 -L5)
  • Fracture age of <8 weeks as indicated by onset of pain or known antecedent traumatic event with corresponding evidence of acuity on MRI (T1 and STIR sequences) or radioisotope bone scan
  • ODI >30/100 at screening visit and VAS >60 at screening visit
  • Failure of conservative management strategies for compression fractures resulting in inadequately controlled pain and/or patient immobility
  • Patient has failed non-operative medical therapy as defined by one of the following definitions set forth by the American College of Radiology:

    1. For a patient rendered nonambulatory as a result of pain from a VCF, pain persisting at a level that prevents ambulation despite 24 hours of analgesic therapy; or
    2. For a patient with sufficient pain from a VCF such that physical therapy is intolerable, pain persisting at that level despite 24 hours of analgesic therapy; or
    3. For a patient with pain from a VCF, unacceptable side effects such as excessive sedation, confusion, or constipation as a result of the analgesic therapy necessary to reduce pain to a tolerable level.
  • Magerl classification A1.1, A1.2, A1.3, A2.1, A2.2 and A3.1 type fractures
  • Appropriate pedicle diameter to receive 5.5mm diameter or 6.5mm diameter implants
  • ASA < 4

Exclusion Criteria:

  • Patient clearly improving on conservative treatment
  • Any contra-indication or allergy to implant material or cement
  • Systemic infection or infection located in the spine
  • Any medical condition including but not limited to anemia, coagulation disorders, fibromyalgia, algoneurodystrophy, Paget's disease, uncontrolled diabetes that would preclude the patient from having surgery or would impede the benefit of surgery
  • Neurologic signs or symptoms related to the fracture or the impeding pathological fracture
  • Any previous surgical treatment (material or cement) in the targeted vertebra
  • Less than one third of the original vertebral body height remaining
  • Unstable fractures or neoplasms with posterior involvement
  • Damages of the pedicles or posterior wall
  • Sclerotic cancellous bone
  • Pedicles not large enough to accept V-STRUT© instrumentation and implants
  • Pregnancy(women of childbearing potential must have a negative pregnancy test to participate)
  • Pre-existing or clinically unstable neurologic deficit
  • Spinal canal compromise causing clinical manifestations of cord, neural foramen, or nerve root compression at the level to be treated
  • Any physical exam evidence of myelopathy or radiculopathy
  • Pain based on clinical diagnosis of herniated nucleus pulposus or severe spinal stenosis (progressive weakness or paralysis)
  • Bedbound prior to incident fracture
  • Any radiographic evidence of pedicle fracture visible on pre-operative imaging
  • Spondylolisthesis >Grade 1 at target VB
  • Any underlying systemic bone disease other than osteoporosis (e.g., osteomalacia, osteogenesis imperfect, Paget's disease, etc.)
  • A medical contraindication to spinal surgery and/or general anesthesia, such as coagulopathy and/or taking warfarin (Coumadin) or other anticoagulant or anti-aggregate (anti-platelet agents) on regular basis for coagulopathy (with a threshold for normal being INR≤1.5, PTT within lab normal range, and platelet count > 100,000)
  • Disabling backpain due to causes other than acute fracture
  • Severe cardiopulmonary deficiencies
  • Any evidence of alcohol or drug abuse
  • Uncontrolled psychiatric illness or severe dementia
  • Involved in medical litigation including workers' compensation

Sites / Locations

  • Johns Hopkins
  • Icahn School of Medicine at Mount SinaiRecruiting
  • St. Luke's
  • West Virginia

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Participants with vertebral compression fractures

Arm Description

Participants with vertebral compression fractures who have failed conservative care strategies.

Outcomes

Primary Outcome Measures

Number of adverse events
Safety will be measured by number of device related serious adverse events using Common Terminology Criteria for Adverse Events (CTCAE) v4.0

Secondary Outcome Measures

Procedure duration
Procedure duration in minutes
Volume of cement injected
volume of cement injected per level
Cement leakage
Presence of cement leakage
Fluoroscopy time
Fluoroscopy dose
Vertebral Height
percentage of vertebral height restoration
Visual Analogue Symptom (VAS)
Pain VAS, full range from 0-100, with higher score indicating more pain
The Oswestry Disability Index
The Oswestry Disability Index is a Low Back Pain Disability Questionnaire frequently used to assess function and very often report in the literature. Full range from 0-100, with higher score indicating more severe disability.
Lost to follow up rate
Study will evaluate the lost to follow up rate to determine statistical methodology and enrollment requirements for any follow up pivotal study

Full Information

First Posted
March 26, 2022
Last Updated
October 11, 2023
Sponsor
Icahn School of Medicine at Mount Sinai
search

1. Study Identification

Unique Protocol Identification Number
NCT05337696
Brief Title
Circumferential Vertebral Reconstruction of Osteoporotic Compression Fractures Using a Novel Bipedicular Peek Implant
Acronym
RECONSTRUCT
Official Title
Circumferential Vertebral Reconstruction of Osteoporotic Compression Fractures Using a Novel Bipedicular Peek Implant
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 10, 2022 (Actual)
Primary Completion Date
December 2024 (Anticipated)
Study Completion Date
December 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Icahn School of Medicine at Mount Sinai

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The RECONSTRUCT study is a multi-center, prospective, single arm, post-market, pilot study to evaluate clinical and radiologic outcome data regarding the use of the Vertebral Implant PEEK (VIP) implant in the treatment of symptomatic, acute (<8week) vertebral compression fractures who have failed conservative care strategies.
Detailed Description
Vertebral compression fractures affect an estimated 1.4 million patients in the world annually and incidence rates rise exponentially with age, especially in women. Outcomes following non-interventional management of these injuries are generally poor, largely as a consequence of opioid requirements, prolonged immobilization, and bedrest. As a result, interventional techniques such as balloon kyphoplasty and vertebroplasty with or without implantable devices are currently regarded as the standard of care for select patients with acute painful osteoporotic compression fractures. These procedures relieve fracture pain by stabilizing the fracture site using cement. Alternative interventional techniques include percutaneous vertebral augmentation, which combine cement injection with implantable devices, such as the SpineJack® and KIVA® devices. The RECONSTRUCT study will build on the outcomes of the SAKOS and KAST clinical trails that evaluated the SpineJack® and KIVA® devices, respectively. The Vertebral Implant PEEK (VIP) implant (V-STRUT© manufactured by Hyprevention) has undergone both clinical and pre-clinical testing. Static and dynamic bending of the implant has been evaluated to demonstrate that the product is capable of supporting in-situ loading, and increase fracture load and energy to fracture. A total of 30 eligible subjects with a diagnosis of osteoporotic fractures of the thoracolumbar spine, as confirmed by MRI scan, and who are treated with the Vertebral Implant PEEK (VIP) device will be asked to join the study. No placebo or control will be utilized during this study. RECONSTRUCT has been designed with the intention of achieving two goals: 1) to inform the design of larger controlled clinical trials in the future and 2) to assess the safety of the study device within the patient sample.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Vertebral Compression Fractures, Osteoporotic Vertebral Compression Fractures

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
2 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Participants with vertebral compression fractures
Arm Type
Experimental
Arm Description
Participants with vertebral compression fractures who have failed conservative care strategies.
Intervention Type
Procedure
Intervention Name(s)
Vertebral Implant PEEK Procedure
Other Intervention Name(s)
Vertebral Implant, VIP
Intervention Description
Vertebral Implant PEEK (VIP) procedure is a minimally invasive/percutaneous vertebral augmentation (PVA), image guided procedure. Two VIP devices are implanted in each to be treated vertebra. A cavity is drilled allowing the introduction of the implant posteriorly through the pedicle and the vertebral body upto the anterior wall. A part of the implant is embedded into the pedicle, thus providing posterior support. The other part of the device, located in the vertebral body, presents a central canula and lateral perforations, which allow acrylic bone cement diffusion, filling of the vertebral body, filling and fixing the implant, and supporting of the upper endplate. The combination of the implant and the cement allows the treatment of vertebral fractures.
Intervention Type
Device
Intervention Name(s)
Vertebral Implant PEEK (VIP) implant
Other Intervention Name(s)
V-STRUT©
Intervention Description
The study device is V-STRUT© Vertebral Implant manufactured by Hyprevention (VIP -Vertebral Implant PEEK), FDA cleared under K191709, indicated for use in the treatment of vertebral fractures in the thoracic and lumbar spine from T9 to L5. It is intended to be used in combination with PMMA bone cement.
Primary Outcome Measure Information:
Title
Number of adverse events
Description
Safety will be measured by number of device related serious adverse events using Common Terminology Criteria for Adverse Events (CTCAE) v4.0
Time Frame
End of study at 18 months
Secondary Outcome Measure Information:
Title
Procedure duration
Description
Procedure duration in minutes
Time Frame
Day 1, at end of procedure
Title
Volume of cement injected
Description
volume of cement injected per level
Time Frame
Day 1, at end of procedure
Title
Cement leakage
Description
Presence of cement leakage
Time Frame
Day 1, at end of procedure
Title
Fluoroscopy time
Time Frame
Day 1, at end of procedure
Title
Fluoroscopy dose
Time Frame
Day 1, at end of procedure
Title
Vertebral Height
Description
percentage of vertebral height restoration
Time Frame
6 months
Title
Visual Analogue Symptom (VAS)
Description
Pain VAS, full range from 0-100, with higher score indicating more pain
Time Frame
6 months
Title
The Oswestry Disability Index
Description
The Oswestry Disability Index is a Low Back Pain Disability Questionnaire frequently used to assess function and very often report in the literature. Full range from 0-100, with higher score indicating more severe disability.
Time Frame
6 months
Title
Lost to follow up rate
Description
Study will evaluate the lost to follow up rate to determine statistical methodology and enrollment requirements for any follow up pivotal study
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥ 50 Osteoporotic compression fractures of the thoracolumbar spine (T9 -L5) Fracture age of ≤ 8 weeks as indicated by onset of pain or known antecedent traumatic event with corresponding evidence of acuity on MRI (T1 and STIR sequences) or radioisotope bone scan ODI ≥ 30/100 at screening visit and VAS ≥ 60 at screening visit Failure of conservative management strategies for compression fractures resulting in inadequately controlled pain and/or patient immobility Patient has failed non-operative medical therapy as defined by one of the following definitions set forth by the American College of Radiology: For a patient rendered nonambulatory as a result of pain from a VCF, pain persisting at a level that prevents ambulation despite 24 hours of analgesic therapy; or For a patient with sufficient pain from a VCF such that physical therapy is intolerable, pain persisting at that level despite 24 hours of analgesic therapy; or For a patient with pain from a VCF, unacceptable side effects such as excessive sedation, confusion, or constipation as a result of the analgesic therapy necessary to reduce pain to a tolerable level. Magerl classification A1.1, A1.2, A1.3, A2.1, A2.2 and A3.1 type fractures Appropriate pedicle diameter to receive 5.5mm diameter or 6.5mm diameter implants ASA < 4 Exclusion Criteria: Patient clearly improving on conservative treatment Any contra-indication or allergy to implant material or cement Systemic infection or infection located in the spine Any medical condition including but not limited to anemia, coagulation disorders, fibromyalgia, algoneurodystrophy, Paget's disease, uncontrolled diabetes that would preclude the patient from having surgery or would impede the benefit of surgery Neurologic signs or symptoms related to the fracture or the impeding pathological fracture Any previous surgical treatment (material or cement) in the targeted vertebra Less than one third of the original vertebral body height remaining Unstable fractures or neoplasms with posterior involvement Damages of the pedicles or posterior wall Sclerotic cancellous bone Pedicles not large enough to accept V-STRUT© instrumentation and implants Pregnancy(women of childbearing potential must have a negative pregnancy test to participate) Pre-existing or clinically unstable neurologic deficit Spinal canal compromise causing clinical manifestations of cord, neural foramen, or nerve root compression at the level to be treated Any physical exam evidence of myelopathy or radiculopathy Pain based on clinical diagnosis of herniated nucleus pulposus or severe spinal stenosis (progressive weakness or paralysis) Bedbound prior to incident fracture Any radiographic evidence of pedicle fracture visible on pre-operative imaging Spondylolisthesis >Grade 1 at target VB Any underlying systemic bone disease other than osteoporosis (e.g., osteomalacia, osteogenesis imperfect, Paget's disease, etc.) A medical contraindication to spinal surgery and/or general anesthesia, such as coagulopathy and/or taking warfarin (Coumadin) or other anticoagulant or anti-aggregate (anti-platelet agents) on regular basis for coagulopathy (with a threshold for normal being INR≤1.5, PTT within lab normal range, and platelet count > 100,000) Disabling backpain due to causes other than acute fracture Severe cardiopulmonary deficiencies Any evidence of alcohol or drug abuse Uncontrolled psychiatric illness or severe dementia Involved in medical litigation including workers' compensation
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Sydney Edwards
Phone
212 241 2524
Email
sydney.edwards@mountsinai.org
First Name & Middle Initial & Last Name or Official Title & Degree
Sukaina Davdani
Phone
212 241 2524
Email
Sukaina.Davdani@mountsinai.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Reade De Leacy, MD
Organizational Affiliation
Icahn School of Medicine at Mount Sinai
Official's Role
Principal Investigator
Facility Information:
Facility Name
Johns Hopkins
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21287
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Majid Khan
First Name & Middle Initial & Last Name & Degree
Majid Khan
Facility Name
Icahn School of Medicine at Mount Sinai
City
New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michael T Caton
First Name & Middle Initial & Last Name & Degree
Michael T Caton
Facility Name
St. Luke's
City
Bethlehem
State/Province
Pennsylvania
ZIP/Postal Code
18015
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Martin Oselkin
First Name & Middle Initial & Last Name & Degree
Martin Oselkin
Facility Name
West Virginia
City
Morgantown
State/Province
West Virginia
ZIP/Postal Code
26506
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
SoHyun Boo
First Name & Middle Initial & Last Name & Degree
SoHyun Boo

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
Upon the completion of the study, Mount Sinai's data management team will clean and analysis all data in preparation of manuscript writing and publication. The intention will be to publish together between the principal investigator and the sponsor. Following publication, Mount Sinai will archive and store all associated data on it's cloud-based system

Learn more about this trial

Circumferential Vertebral Reconstruction of Osteoporotic Compression Fractures Using a Novel Bipedicular Peek Implant

We'll reach out to this number within 24 hrs